Patent intelligence · US
US 12030908
Antimicrobial compounds, compositions, and uses thereof
Antimicrobial compounds, compositions, and uses thereof
Patent details — US 12030908
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 9, 2024
- Expiration
- Jul 4, 2044
- Applicant
- Lakewood Amedex, Inc.
- Claims
- 22
- CPC classes
- A61P, A61P13/02, A61P15/02, A61P17/00
Quick answer
US 12030908 (Antimicrobial compounds, compositions, and uses thereof) is held by Lakewood Amedex, Inc.. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lakewood Amedex, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61P, A61P13/02, A61P15/02, A61P17/00, A61P27/16, A61P31/04
More from Lakewood Amedex, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11377468
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 11096954
Bisphosphocin gel formulations and uses thereof
granted -
US 10981943
Antimicrobial compounds, compositions, and uses thereof
granted
Frequently asked questions
What is US patent 12030908?
US 12030908 (Antimicrobial compounds, compositions, and uses thereof) is held by Lakewood Amedex, Inc.. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12030908?
Lakewood Amedex, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 12030908 expire?
Our index shows an expiration date of Jul 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.